Systemic Triple Therapy in Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

For many years, androgen deprivation therapy (ADT) as monotherapy Rubber Hose Collar has been the gold standard for metastatic hormone-sensitive prostate cancer (mHSPC) treatment.Several studies have been published within the last decade demonstrating a significant survival advantage resulting from combining the treatment with standard ADT plus docetaxel or androgen receptor targeted therapy (ARTA) compared to ADT monotherapy.Recently published data of the PEACE-1 and ARASENS trials suggest that in Toy Ponies the future, triple therapy might be a treatment option for patients with mHSPC.